Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use of pegfilgrastim in severe chronic neutropenia
2024-519009-36-01Phase 2Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in severe chronic neutropenia (SCN), sponsored by Istituto Giannina Gaslini. Primary endpoint: Median absolute neutrophil count. Planned start Jan 2025; status: authorised.
02
Drugs
pegfilgrastim
03
Conditions
severe chronic neutropenia (SCN)
Beyond the preview
Go deeper on 2024-519009-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519009-36-01.